Doximity's stock plummets 14% despite strong Q1 results, as Q2 guidance falls short of expectations amid policy uncertainties in the pharmaceutical industry.
#YonhapInfomax #Doximity #Q1Earnings #StockPlunge #GuidanceDisappointment #PharmaceuticalIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=63653
#YonhapInfomax #Doximity #Q1Earnings #StockPlunge #GuidanceDisappointment #PharmaceuticalIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=63653